期刊文献+

临床药师参与中性粒细胞减少肿瘤患者的抗菌治疗 被引量:2

Clinical Pharmacist Participates in the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
下载PDF
导出
摘要 通过临床药师参与会诊1例中性粒细胞减少伴发热的肿瘤患者,并对其抗感染治疗实践做回顾性分析,介绍临床药师如何在指南的引导下参与抗感染治疗实践,并分享经验。临床药师对指南的深刻理解并注重结合临床实际,对提高临床药师诊治水平、优化抗菌治疗方案等有非常重要的意义。 By retrospectively analyzing a case of clinical pharmacist participated-consultation and anti-infection treatment for an oncology patient with neutropenia and fever,introducing how clinical pharmacist participate pharmacotherapy under the guidance and share work experience.For pharmacists,deeply understanding of the guideline and combining with clinical experience are of great importance to improve diagnosis-and-treatment level and to optimize antimicrobial therapy.
作者 蒋倩 蒋刚
出处 《药品评价》 CAS 2013年第16期17-19,共3页 Drug Evaluation
关键词 临床药师 中性粒细胞减少 发热 指南 Clinical Pharmacist Neutropenia Fever Guideline
  • 相关文献

参考文献5

  • 1Freifeld AG, Bow E J, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis. 2011 ;52(4):e56-93.
  • 2Baden LR, Bensinger W, Angarone M, et al.Prevention and treatment of cancer-related infections[J]. J Natl Compr Canc Netw. 2012;10(11):1412-45.
  • 3四川美康医药软件研究开发公司.药物临床信息参考[M].重庆:重庆出版社,2008.127-128.
  • 4方向群,刘长庭.呼吸系统感染治疗对策[M].北京:科学出版社,2010:3.
  • 5徐英春,肖永红,卓超,郑波,王辉,杨启文.中国碳青霉烯类耐药肠杆菌科细菌的流行病学和防控策略[J].中国执业药师,2013(4):3-8. 被引量:92

二级参考文献32

  • 1骆俊,朱德妹,徐晓刚,吴卫红,王明贵,张婴元,汪复.泛耐药弗劳地柠檬酸杆菌产β内酰胺酶及同源性[J].中华传染病杂志,2006,24(5):291-295. 被引量:20
  • 2Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections[J]. Crit Care, 2008,12 ($4) : 5.
  • 3Yigit H, Queenan AM, Anderson GJ, et al. Novel earbapen- em-hydrolyzing beta-laetamase, KPC-1, from a earbapenem-re- sistant strain of Klebsiella pneumoniae [J]. Antimierob Agents Chemother,2001,45(4) : 1151-1161.
  • 4Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evi- dence[J]. Euro Surveill, 2008,13 (4), pii : 8023.
  • 5Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipen- em resistance in clinical Escherichia coli during therapy[J], lnt J Antimicrob Agents, 2008,32 (6) : 534-537.
  • 6Kaczmarek FM, Dib-Hajj F, Shang W, et al. High-level carbapen- em resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla (ACT-1) beta-lactamase production ,porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe [J]. Antimicrob Agents Chemoth- er, 2006,50 (10) : 3396-3406.
  • 7Queenan AM, Bush K. Carbapenemases: the versatile beta-lacta- mases[J]. Clin Mierobiol Rev, 2007,20 (3) : 440-458.
  • 8Yigit H, Anderson G J, Biddle JW, et al. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with de- creased expression of OmpF and OmpC porin analogs[J]. Antimi- crob Agents Chemother, 2002,46 ( 12 ) : 3817-3822.
  • 9Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams[J]. J Antimicrob Chemother, 1997,40 (3) : 365-370.
  • 10Castanheira M, Mendes RE, Woosley LN, et al. Trends in car- bapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas : report from the SENTRYantimicrobial surveillance programme (2007-09)[J]. J Antimicrob Chemother, 2011,66(6) : 1409-1411.

共引文献99

同被引文献22

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部